Your browser doesn't support javascript.
loading
A 28-day oral toxicity evaluation of small interfering RNAs and a long double-stranded RNA targeting vacuolar ATPase in mice.
Petrick, Jay S; Moore, William M; Heydens, William F; Koch, Michael S; Sherman, James H; Lemke, Shawna L.
Afiliação
  • Petrick JS; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA. Electronic address: jay.s.petrick@monsanto.com.
  • Moore WM; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA.
  • Heydens WF; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA.
  • Koch MS; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA.
  • Sherman JH; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA.
  • Lemke SL; Monsanto Company, 800 North Lindbergh Boulevard, Creve Coeur, MO 63167, USA.
Regul Toxicol Pharmacol ; 71(1): 8-23, 2015 Feb.
Article em En | MEDLINE | ID: mdl-25445299
ABSTRACT
New biotechnology-derived crop traits have been developed utilizing the natural process of RNA interference (RNAi). However, plant-produced double stranded RNAs (dsRNAs) are not known to present a hazard to mammals because numerous biological barriers limit uptake and potential for activity. To evaluate this experimentally, dsRNA sequences matching the mouse vATPase gene (an established target for control of corn rootworms) were evaluated in a 28-day toxicity study with mice. Test groups were orally gavaged with escalating doses of either a pool of four 21-mer vATPase small interfering RNAs (siRNAs) or a 218-base pair vATPase dsRNA. There were no treatment-related effects on body weight, food consumption, clinical observations, clinical chemistry, hematology, gross pathology, or histopathology endpoints. The highest dose levels tested were considered to be the no observed adverse effect levels (NOAELs) for the 21-mer siRNAs (48 mg/kg/day) and the 218 bp dsRNA (64 mg/kg/day). As an additional exploratory endpoint, vATPase gene expression, was evaluated in selected gastrointestinal tract and systemic tissues. The results of this assay did not indicate treatment-related suppression of vATPase. The results of this study indicate that orally ingested dsRNAs, even those targeting a gene in the test species, do not produce adverse health effects in mammals.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA de Cadeia Dupla / ATPases Vacuolares Próton-Translocadoras / RNA Interferente Pequeno Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA de Cadeia Dupla / ATPases Vacuolares Próton-Translocadoras / RNA Interferente Pequeno Idioma: En Ano de publicação: 2015 Tipo de documento: Article